Carisma Therapeutics Overview

  • Founded

  • 2016

Founded
  • Status

  • Public

  • Employees

  • 72

Employees
  • Stock Symbol

  • CARM

Stock Symbol
  • Investments

  • 1

  • Share Price

  • $3.03

  • (As of Wednesday Closing)

Carisma Therapeutics General Information

Contact Information

Website
www.carismatx.com
Formerly Known As
Carma Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 3675 Market Street
  • Suite 200
  • Philadelphia, PA 19104
  • United States
+1 (484) 000-0000

Carisma Therapeutics Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Carisma Therapeutics Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.03 $2.98 $2.77 - $5.88 $122M 40.3M 197K
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Carisma Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Carisma Therapeutics‘s full profile, request access.

Request a free trial

Carisma Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion
Price		 % Owned

This information is available in the PitchBook Platform. To explore Carisma Therapeutics‘s full profile, request access.

Request a free trial

Carisma Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Drug Discovery
Philadelphia, PA
72 As of 2022
00000
000000000 00000

000000

m dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proiden
0000000000000
South San Francisco, CA
00 As of 0000
000.00
00000000000 000.00

000000

is nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehender
0000000000000
Utrecht, Netherlands
00 As of 0000
00.000
0000000000 0 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Carisma Therapeutics Competitors (38)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Amphivena Therapeutics Venture Capital-Backed South San Francisco, CA 00 000.00 00000000000 000.00
000000 Venture Capital-Backed Utrecht, Netherlands 00 00.000 0000000000 0 00.000
0000000 0000000000 Venture Capital-Backed Bedford, MA 00 000.00 0000000000 0 000.00
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
0000000 000000000 Venture Capital-Backed Vienna, Austria 00 000.00 0000000000 0
You’re viewing 5 of 38 competitors. Get the full list »

Carisma Therapeutics Patents

  • 10

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 1

    Granted

  • 3

    Pending

  • 000

    Expiring in next 12 mo

Carisma Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021331368-A1 Modified immune cells for fibrosis and inflammation Pending 28-Aug-2020 000000000
CA-3192646-A1 Modified immune cells for fibrosis and inflammation Pending 28-Aug-2020
AU-2021296914-A1 Mrna transfection of immune cells Pending 26-Jun-2020 0000000000
CA-3187138-A1 Mrna transfection of immune cells Pending 26-Jun-2020 0000000000
AU-2021285992-A1 Novel constructs for chimeric antigen receptors Pending 04-Jun-2020 A61P35/00
To view Carisma Therapeutics’s complete patent history, request access »

Carisma Therapeutics Executive Team (14)

Name Title Board Seat Contact Info
Steven Kelly President, Chief Executive Officer & Board Member
Daniel Cushing Ph.D Chief Technology & Development Officer & Vice President
Michael Klichinsky Ph.D Co-Founder & Chief Scientific Officer
Elena Petrossian Financial Controller
Tom Wilton Chief Business Officer
You’re viewing 5 of 14 executive team members. Get the full list »

Carisma Therapeutics Board Members (16)

Name Representing Role Since
Björn Odlander Ph.D HealthCap Board Member 000 0000
Briggs Morrison MD Self Board Member 000 0000
Chidozie Ugwumba Self Board Member 000 0000
Geeta Vemuri Ph.D Agent Capital Board Observer 000 0000
Margarita Chavez JD AbbVie Ventures Board Member 000 0000
You’re viewing 5 of 16 board members. Get the full list »

Carisma Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Carisma Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Carisma Therapeutics‘s full profile, request access.

Request a free trial

Carisma Therapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 000 07-Mar-2023 0000000000 Drug Discovery 000000 00
To view Carisma Therapeutics’s complete acquisitions history, request access »